GeneDx (NASDAQ:WGS – Get Free Report) and AdaptHealth (NASDAQ:AHCO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
Institutional and Insider Ownership
61.7% of GeneDx shares are owned by institutional investors. Comparatively, 82.7% of AdaptHealth shares are owned by institutional investors. 25.2% of GeneDx shares are owned by company insiders. Comparatively, 1.9% of AdaptHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares GeneDx and AdaptHealth”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $427.54 million | 3.92 | -$21.02 million | ($3.64) | -15.43 |
| AdaptHealth | $3.35 billion | 0.25 | -$70.79 million | ($1.71) | -3.52 |
GeneDx has higher earnings, but lower revenue than AdaptHealth. GeneDx is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GeneDx and AdaptHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | -23.41% | 4.12% | 2.26% |
| AdaptHealth | -7.07% | 3.36% | 1.16% |
Volatility & Risk
GeneDx has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, AdaptHealth has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for GeneDx and AdaptHealth, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 1 | 1 | 7 | 0 | 2.67 |
| AdaptHealth | 1 | 1 | 7 | 0 | 2.67 |
GeneDx currently has a consensus target price of $90.86, indicating a potential upside of 61.81%. AdaptHealth has a consensus target price of $10.14, indicating a potential upside of 68.49%. Given AdaptHealth’s higher probable upside, analysts clearly believe AdaptHealth is more favorable than GeneDx.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
About AdaptHealth
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
